Molecular Partners appoints Göran Ando as independent non executive board member

Molecular Partners AG, the global leader in the development of DARPins as unique next generation protein therapeutics, announced today the appointment of Dr Göran Ando as independent non-executive member of the board of directors.

Dr Ando brings considerable experience to the board of Molecular Partners, having been CEO of Celltech Group, plc. Prior to this, he was Executive Vice President and President R&D for Pharmacia, now Pfizer Inc., where he was also responsible for manufacturing, IT, business development and Mergers & Acquisitions. He has also held positions as R&D Director of Glaxo Group, UK, and was a member of the Glaxo Group Executive Committee. He currently serves as Vice Chairman of the Board of Directors of Novo Nordisk A/S and as Senior Advisor to Essex Woodlands Health Ventures. Dr Ando is a Physician and Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the US.

Jörn Aldag, Chairman of the Board of Directors at Molecular Partners said: “I am delighted to welcome Göran to the board of Molecular Partners. He brings with him a wealth of scientific and general management experience at a time where Molecular Partners is transitioning from a pre-clinical to a clinical stage product development company. He will prove invaluable to Molecular Partners in supporting many of our portfolio decisions as the Company continues to expand.”

Dr Göran Ando added: “This is an exciting time to be joining Molecular Partners. Having secured deals with major pharmaceutical partners, one of the largest fundraisings in Europe last year, and with their first products entering the clinic, the Company is in an excellent position, and I look forward to being part of its continued success.”